⚡ Catalyst · Weekly Watchlist

⚠️ THESIS BROKEN — this report replaces the Jul 14 version, which modelled a Base case of +70% to $35.04 on the assumption the FDA advisory committee would go Capricor's way. It did not. An FDA briefing document on Jul 27 challenged the statistical validity of the Phase 3 HOPE-3 results, and the AdCom then voted 9-3 that the evidence does NOT establish deramiocel's effectiveness in DMD cardiomyopathy. The stock fell from $22.43 (Jul 6) to $4.19 — down 81% — analysts cut targets from the $38-63 range into single digits, and securities fraud class actions have been filed. The Aug 22 PDUFA still stands and the AdCom vote is formally non-binding, so a surprise approval is not impossible, but the base case is now a CRL. At $4.19 this is ค่าขนม — a lottery ticket on an FDA reversal, not a position.

Zymeworks' zanidatamab (marketed as Ziihera, partnered with Jazz Pharmaceuticals) already has FDA approval in 2nd-line HER2+ biliary tract cancer since Nov 2024. The Aug 25, 2026 PDUFA date is for a supplemental BLA adding first-line HER2+ gastroesophageal adenocarcinoma (GEA) — a much larger population — backed by a positive Phase 3 (HERIZON-GEA-01: median PFS 12.4 vs 8.1 months, HR 0.63, p<.0001) and Priority Review status. Approval unlocks a $250M US milestone (of $440M total) plus a materially bigger royalty base, but the Q2 revenue miss shows the current BTC business alone is still thin, and the payout flows through Jazz as milestones/royalties, not full commercial upside.

Red Cat's Q2 2026 revenue grew 527% YoY to $20.19M, but missed Street consensus and the stock fell -5.4% on the print as the net loss widened to $35.26M. The real structural story is the U.S. Army SRR Program of Record win (up to 5,880 Teal systems over 5 years) plus steady contract flow — including a $2.49M Air Force Black Widow order due for delivery by Aug 24, 2026. Consensus analyst targets ($16.50-$22) imply 72-129% upside, but at ~61x sales the market is already pricing in a clean production ramp that Q2's miss puts some doubt on.

⚠️ This snapshot is PRE-RESULTS — Firefly reports Q2 2026 earnings TOMORROW, Aug 11, 2026. The stock has run hard into the print, up 11.0% on Aug 7 alone to $26.71, extending gains that trace back partly to the successful Alpha Flight 7 launch (Mar 2026, +12.77% same-day) which validated key Block II upgrades ahead of the full Block II debut still planned for Flight 8. FY26 guidance ($420-450M, 80% pre-booked via a $1.3B backlog) should still hold from the Q1 print; the real swing factor tomorrow is execution commentary and any update on Alpha Block II's still-undated Flight 8 debut. Consensus (MarketBeat, 12 analysts) sits at $40.64 (~52% upside from here), with a $60 high estimate.

Broadcom is consolidating just below the $427-ish level it rallied to on Aug 4's AI-demand relief rally (Palantir's blowout quarter reassured the market broadly), down a modest 0.62% today. The one concrete update since the last report: Q3 FY26 earnings are now confirmed for Sep 2, 2026 (the company's own official date), resolving the prior uncertainty between Sep 2 and Sep 3. The core, unresolved question is unchanged — whether the Jun 4 Google ASIC-diversification concern is overblown, as the market is now betting via proxy — and won't be answered until that Sep 2 print. 48 analysts still average a ~$527.88 target (Strong Buy, zero Sell), implying meaningful upside from here.

The transition thesis is now largely proven rather than promised: IREN has secured $2.8B in new multi-year contracts covering 85% of its $4B 2026 ARR target, with Microsoft and NVIDIA among the named customers, and plans 480MW of AI cloud capacity in 2026 rising to 1.2GW in 2027. That is a different company from the Bitcoin miner the ticker used to represent. Consensus is $75.18 (range $46-$100; a 16-analyst S&P set reads higher at $81.73), so upside is +72% or better and the rating split is 62% Strong Buy. The problem is entirely the entry: after a 9.86% move today the stock trades 30.4% above its preferred zone, going into Q4 FY2026 earnings on Aug 27.

Marvell's stock is consolidating near the level it rallied to on the FMS 2026 AI-memory portfolio launch (Aug 3-4), with two incremental positives since: a $250M, 3-year commitment to expand India R&D headcount (Bangalore/Hyderabad) deepening the AI-semiconductor engineering base, and reports the FCC may ban new Chinese optical transceivers — a policy tailwind for non-Chinese suppliers like Marvell if it happens. Morgan Stanley flagged Google's potential 'Frozen v2' AI chip as a future custom-silicon opportunity but kept an Equal Weight ($195 target, below consensus). Q2 FY2027 earnings land Aug 27, 2026, with an Investor Day following Oct 6 — both still the real near-term proof points; today's move is incremental follow-through, not a new step-change catalyst.

Consensus across the largest analyst sets is $302.83 (61 analysts, Strong Buy), with wider polls reading $316.79 (67) and $319 (79) — call it +35% from here against a $180 low and $500 high. Q2 FY2027 earnings land Aug 26, with the Vera Rubin shipment ramp behind it as the second leg. The thesis is unchanged and unusually well-supported for a $5.4T company; the issue is that the stock has run 5.7% in eight days into the print and now sits 13.5% above the entry zone. Note the measured reality check: this dashboard's earnings_beat bucket has an 0% hit rate on +30%/14d across 42 completed windows — a mega-cap moving 30% in two weeks is close to physically impossible, so treat the consensus target as a 12-month figure, not a catalyst-window one.

Planet's Q1 FY2027 was a genuine inflection: record revenue of $94.2M, up 42% YoY, driven by defence & intelligence contracts growing over 65%. That shifts the story from 'imagery subscriptions with slow growth' to 'defence data supplier with government budget behind it'. Consensus sits around $35.36 across 10 analysts (median $38 on a narrower 5-analyst set, range $22-$53) — roughly +44% from here. The catch is entry, not thesis: the stock has run 7.3% in eight days and now trades 16.7% above the $19-21 zone the last report set. Q2 FY2027 earnings on Sep 8 is the next test.

AeroVironment's Q1 FY2026 print (late June 2026) was a clean beat — revenue $641.6M vs $559.4M est. (+133% YoY), adjusted EPS $1.84 vs $1.47 est. — and the stock jumped ~19% same-day. Since then, the post-BlueHalo combined entity ($4.1B merger, completed May 2025) has kept landing real, dated contract wins: a $186M Army Switchblade order (Feb 2026), a $200M ESAero acquisition (Mar 2026), and a $117M Army P550 order (2026). Sept 9, 2026 earnings is the next real catalyst to confirm the growth rate is holding as BlueHalo's Golden Dome-relevant directed-energy/space/cyber lines scale alongside the legacy drone business.